ABSTRACT
Objective To investigate the effects of NovoRapid and biosynthetic human insulin (Novolin-R) on serum cystatin C (Cys C) and homocysteine (HCY) and pregnancy outcome in pregnant women with gestational diabetes mellitus (GDM). Methods A total of 216 cases of GDM pregnant women admitted to our hospital from February 2017 to December 2018 were selected. The patients were divided into observation group (n=112) and control group (n=104) according to the random number table method. Patients in the observation group received NovoRapid treatment, and patients in the control group received Novolin-R treatment. Results The blood glucose compliance time of observation group was significantly shorter than that of control group (P0.05). Conclusion The efficacy of NovoRapid in the treatment of GDM is better than Novolin-R, which could better control blood glucose levels, reduce serum Cys C and HCY levels, and improve pregnancy outcomes. The NovoRapid treatment is worthy of clinical promotion and application.